Ruyuan Hec Pharm is an API manufacturer based in China. It holds 21 active US drug master files across a filed portfolio of 20 molecules. Its GMP standing is certified by EMA and US FDA. Its most recent recorded inspection, by US FDA, closed on 22 November 2024 as NAI.
NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.
| Site | FDA FEI |
|---|---|
| China, China | 3009740510 |
| Shaoguan City, Ruyuan County, Guangdong Province, China | Not on file |
| Molecule | Regulators | Docs |
|---|---|---|
| Sitagliptin | SFDA (Saudi Arabia), US FDA | 4 |
| Fingolimod | SFDA (Saudi Arabia), US FDA | 2 |
| Rosuvastatin | US FDA | 2 |
| Alogliptin | US FDA | 1 |
| Apixaban | US FDA | 1 |
| Apremilast | US FDA | 1 |
| Aripiprazole | US FDA | 1 |
| Brivaracetam | US FDA | 1 |
| Escitalopram | US FDA | 1 |
| Linagliptin | US FDA | 1 |
| Linagliptin And | SFDA (Saudi Arabia) | 1 |
| Oseltamivir | US FDA | 1 |
| Prasugrel | US FDA | 1 |
| Ritonavir | US FDA | 1 |
| Rivaroxaban | US FDA | 1 |
| Sofosbuvir | SFDA (Saudi Arabia) | 1 |
| Solifenacin Succinate | US FDA | 1 |
| Sugammadex | US FDA | 1 |
| Tadalafil | US FDA | 1 |
| Vonoprazan | US FDA | 1 |
Also appears on these molecule pages
| Regulator | Filings | GMP certificates |
|---|---|---|
| MINSA (CR) | 2 | None |
| EMA | None | 1 |
| US FDA | None | 1 |
Choose your molecules and target markets. Ruyuan Hec Pharm comes back tiered against every other supplier able to file there.
Start for free